MedPath

BI-1291583

Generic Name
BI-1291583
Clinical Trials
Related News

A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

Phase 1
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2025-04-09
Last Posted Date
2025-05-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT06917872
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-04-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT06791187
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Phase 3
Not yet recruiting
Conditions
Bronchiectasis
Interventions
Drug: Placebo matching BI 1291583
First Posted Date
2025-03-12
Last Posted Date
2025-05-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1680
Registration Number
NCT06872892
Locations
🇧🇬

Medical Center "Pulmovision", Sofia, Bulgaria

🇯🇵

Matsue Medical Center, Shimane, Matsue, Japan

🇧🇬

Medical Center Tara, Veliko Tarnovo, Bulgaria

and more 389 locations

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-08
Last Posted Date
2025-05-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT06631417
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: [14C]-BI 1291583
First Posted Date
2023-12-12
Last Posted Date
2024-02-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT06166992
Locations
🇳🇱

ICON, Groningen, Netherlands

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Phase 2
Completed
Conditions
Cystic Fibrosis
Bronchiectasis
Interventions
Drug: Placebo
First Posted Date
2023-05-19
Last Posted Date
2024-11-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
22
Registration Number
NCT05865886
Locations
🇪🇸

Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain

🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

🇺🇸

Northwell Health Physician Partners, New York, New York, United States

and more 9 locations

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Phase 2
Active, not recruiting
Conditions
Bronchiectasis
Interventions
Drug: Placebo matching BI 1291583
First Posted Date
2023-05-06
Last Posted Date
2025-04-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
269
Registration Number
NCT05846230
Locations
🇧🇬

Medical Center "Zdrave-1", Kozloduy, Bulgaria

🇧🇬

Medica Center Hera - Montana Branch, Montana, Bulgaria

🇧🇬

Medical Center ReSpiro Ltd, Razgrad, Bulgaria

and more 99 locations

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Phase 2
Completed
Conditions
Bronchiectasis
Interventions
Drug: Placebo
First Posted Date
2022-02-14
Last Posted Date
2025-04-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
322
Registration Number
NCT05238675
Locations
🇳🇱

Amsterdam UMC, location VUMC, Amsterdam, Netherlands

🇪🇸

Hospital de Mérida, Mérida, Spain

🇺🇸

Malcom Randall VA Medical Center, Gainesville, Florida, United States

and more 107 locations

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-01-10
Last Posted Date
2022-08-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT05183347
Locations
🇯🇵

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2021-04-29
Last Posted Date
2021-12-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT04866160
Locations
🇩🇪

Fraunhofer ITEM, Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy